#### VIEWPOINT



# The COVID-19 infection: lessons from the Italian experience

Paola Romagnani<sup>1</sup> · Guido Gnone<sup>2</sup> · Francesco Guzzi<sup>1</sup> · Simone Negrini<sup>3</sup> · Andrea Guastalla<sup>3</sup> · Francesco Annunziato<sup>1</sup> · Sergio Romagnani<sup>1</sup> · Raffaele De Palma<sup>3</sup>

Published online: 29 May 2020 © Springer Nature Limited 2020

#### **Abstract**

The first case of the new coronavirus, COVID-19, was reported in China on 17 November 2019. By the end of March 2020, the rapid global spread of infection affected over 1 million people. Italy is one of the countries most impacted, with over 100,000 positive cases identified. The first detected cases were reported on 21 February 2020 in two Italian towns: Vo' Euganeo in the Province of Padua, Veneto region, and Codogno, in the Province of Lodi, Lombardy. In the next weeks the epidemic spread quickly across the country but mainly in the north of Italy. The two regions: Veneto and Lombardy, implemented different strategies to control the viral spread. In Veneto, health personnel tested both symptomatic and asymptomatic subjects, while in Lombardy only symptomatic cases were investigated. We analyzed the evolution of the epidemic in these regions and showed that testing both symptomatic and asymptomatic cases is a more effective strategy to mitigate the epidemic impact. We strongly recommend that decision-makers:

- ensure early isolation of symptomatic patients and rapid identification of their contacts;
- maximize testing rapidly, especially among people with multiple daily contacts with infected populations, high exposure to the public in essential services;
- rapidly increase diagnostic capacity by mobilizing trained personnel capable of performing rRT-PCR on respiratory samples;
- equip the population with protective masks.

### **Keywords** COVID-19 · Pandemic · Virus spread

Sergio Romagnani and Raffaele De Palma are the first authors.

- Sergio Romagnani sergio.romagnani@unifi.it
- Raffaele De Palma raffaele.depalma@unige.it

Extended author information available on the last page of the article



#### Introduction

The earliest known case of the coronavirus disease 2019, now abbreviated as COVID-19 ('CO' stands for 'corona,' 'VI' for 'virus,' and 'D' for disease; formerly, this disease was referred to as "2019 novel coronavirus" or "2019-nCoV"), occurred on the 17 of November 2019 in Wuhan, the capital of the Hubei province in China. The appearance of this new coronavirus was made known by the Chinese authorities a few weeks later, in December 2019 [1]. Infection from the virus can be asymptomatic or develop into flu-like symptoms, including fever, cough, and shortness of breath [2, 3]. In some cases, the disease progresses to a severe acute respiratory syndrome, pneumonia, multi-organ failure, and death [4]. The virus spreads mainly via respiratory droplets from coughs and sneezes [5]. The standard method of testing the presence of infection with COVID-19 is real-time reverse transcription polymerase chain reaction (rRT-PCR) performed on respiratory samples obtained by nasopharyngeal swab or sputum samples [6, 7], with results of the test becoming available within a few hours to two days. Following its appearance in China, the COVID-19 infection rapidly spread to countries close to China, including South Korea, Singapore, and others. Due to its high infectivity, it has now spread globally, resulting in the 2019-2020 coronavirus pandemic [4].

## The Italian experience

The disease appeared for the first time in Italy in the small city of Codogno (Lombardy) in a young man of 38 years, who was defined by health personnel as Patient 1. He went to the hospital emergency room of Codogno at least twice on 18 and 19 February with flu-like symptoms but staff did not recognize his infection as COVID-19. Thus, he spread the infection to many people present in the emergency room, including medical personnel, before being hospitalized because his condition became very severe. On 21 February 2020, the authorities of Lombardy declared a lockdown for the area of Codogno, Lodi, and Casalpusterlengo, then named a "red zone." At the same time, symptomatic infected people also appeared in the small village of Vò Euganeo, close to Padua in the region of Veneto. That village quickly imposed complete restriction of movement. Beginning at this time, the strategies to prevent the spread of infection in the regions of Lombardy and Veneto diverged. Lombardy tested only symptomatic people for the COVID-19 infection; in Vò Euganeo, health personnel screened and tested the entire population, whether people were symptomatic or not.

These different strategies determined the impact of infection in the two regions. In Lombardy, where medics tested only symptomatic subjects by nasopharyngeal swab or sputum sample, the number of infected persons rapidly increased



240 P. Romagnani et al.

and many patients developed severe respiratory disease, requiring intensive care. Then, another unfortunate and mismanaged case of infection in the hospital emergency room of Alzano Lombardo, a village of Lombardy, triggered an even greater virus spread through the city of Bergamo. On 21 March 2020—about one month after the discovery of Patient 1 in Codogno—the total number of symptomatic patients in Lombardy exceeded 17,000, more than 5000 of those recovered, and about 3500 had died. We attribute this incredibly high rate of lethality, exceeding 20%, to several factors. To some extent, high mortality could be due to the age of the population and a long average lifespan in Italy. However, the main reason is likely to be the lack of mass testing and miscalculation by health authorities of how many infected people were asymptomatic.

In the Vò Euganeo village, mass testing and isolation of the infected yet asymptomatic people resulted in the reduction of the infected people from 2.6 to 0.3% (more than ten times lower) and the rapid disappearance of the infection. A study performed by Dr. Andrea Crisanti clearly demonstrated that among Vò's residents 43.2% were infected but asymptomatic. The study also shows, that an early isolation of symptomatic patients reduced the average duration of the disease (personal communication). The regional health authorities applied the early isolation strategy to all the cities of the Veneto region. On 21 March the number of infected people in this region had reached about 4500 and 170 had died. This lethality rate of 4% was much lower compared to Lombardy.

We compiled data on the number of tests performed, positive tests, deaths, testing success (a ratio of positive tests and total tested) and case fatality rate (CRF) (a ratio of deaths and positive tests) in 14 regions of Italy with more than 10 deaths due to COVID-19 as of 22 March 2020 (Table 1). We observed a strong relationship between the COVID-19 testing success, measured as a fraction of positive tests among all tested, and case fatality rate (CFR) (Spearman rank correlation coefficient  $\rho$ =0.657; p<0.01). Among 14 selected regions of Italy, the difference between Lombardy and Veneto regions in both sampling success and CFR is quite apparent (Fig. 1). While the population of Lombardy is twice of the Veneto (10 M vs 4.5 M), the number of tests per capita performed in Veneto was almost two times higher than in Lombardy. Similarly, the death rate due to COVID-19 in Veneto was two times lower than in Lombardy (181.3 and 344.9 cases per million population).

The observations from Vò Euganeo are in agreement with COVID-19 data observed on a large scale and potentially explain the marked discrepancies in outbreak severity across countries. For instance, South Korea is similar to Italy in both the population (55 million and 60 million, respectively) and the average life expectancy (82 and 83.4 years, respectively), yet the impact of COVID-19 is different. The number of infected people in South Korea totalled 9000 with about 110 deaths equivalent to a lethality rate of 1.2%. As of March, more than 300,000 people had been tested in South Korea. The results showed that 55% of asymptomatic infected people were responsible for the 80% of symptomatic patients. Among infected, 33% were in the age range of 20 through 29 years (Data mentioned in the text were taken,



**Table 1** The number of tests, positive tests, deaths, testing success (a ratio of positive tests and total tested) and case fatality rate (CRF) (a ratio of deaths and positive tests) 15 regions of Italy and 21 countries with 10 or more cases of death due to COVID-19

Locations	Date	Total tests	Positive tests	Deaths	Deaths/posi- tive tests	Positive tests/ total tests
15 Italian regions (w	ith > 10 deaths) <sup>a</sup>					
Lombardy	22.03.2020	70,598	27,206	3456	0.127	0.385
Emilia Romagna	22.03.2020	28,022	7555	816	0.108	0.270
Veneto	22.03.2020	57,671	5122	169	0.033	0.089
Piemonte	22.03.2020	12,701	4420	283	0.064	0.348
Marche	22.03.2020	6391	2421	184	0.076	0.379
Toscana	22.03.2020	13,264	2277	91	0.040	0.172
Liguria	22.03.2020	4995	1665	171	0.103	0.333
Lazio	22.03.2020	17,845	1383	53	0.038	0.078
Campania	22.03.2020	4943	936	29	0.031	0.189
Friuli V.G.	22.03.2020	6761	874	47	0.054	0.129
Trento	22.03.2020	3050	954	35	0.037	0.313
Bolzano	22.03.2020	5718	678	23	0.034	0.119
Puglia	22.03.2020	6160	786	31	0.039	0.128
Abruzzo	22.03.2020	3375	587	33	0.056	0.174
Umbria	22.03.2020	3135	521	16	0.031	0.166
21 Countries (with>	10 deaths) <sup>b</sup>					
Italy	3.04.2020	619,849	115,242	13,917	0.121	0.186
Indonesia	4.04.2020	7986	1986	181	0.091	0.249
UK	3.04.2020	173,784	33,722	2961	0.088	0.194
Netherlands	2.04.2020	75,415	13,614	1173	0.086	0.181
France	31.03.2020	224,254	58,327	4490	0.077	0.260
Belgium	3.04.2020	67,945	15,348	1011	0.066	0.226
Ecuador	2.04.2020	9604	2372	146	0.062	0.247
Denmark	3.04.2020	39,928	3386	123	0.036	0.085
Japan	3.04.2020	39,446	2617	65	0.025	0.066
India	27.03.2020	26,798	724	17	0.023	0.027
USA	3.04.2020	1,267,658	213,600	4793	0.022	0.168
Turkey	3.04.2020	141,716	18,135	356	0.020	0.128
Ireland	31.03.2020	30,213	2910	54	0.019	0.096
South Korea	3.04.2020	443,273	10,062	174	0.017	0.023
Malaysia	3.04.2020	47,723	3116	50	0.016	0.065
Pakistan	3.04.2020	30,308	2450	35	0.014	0.081
Austria	4.04.2020	104,134	11,129	158	0.014	0.107
Canada	1.04.2020	256,933	11,372	152	0.013	0.044
Estonia	3.04.2020	19,091	858	11	0.013	0.045
Germany	29.03.2020	918,460	52,547	389	0.007	0.057
Australia	3.04.2020	277,278	5224	23	0.004	0.019

<sup>&</sup>lt;sup>a</sup>Data source: www.protezionecivile.gov.it/

<sup>&</sup>lt;sup>b</sup>Data sources: for total tests performed—https://ourworldindata.org/ and for positive tests and deaths—www.who.int/



242 P. Romagnani et al.




Fig. 1 The relationship between COVID-19 testing success (a ratio of positive tests and total tested) and case fatality rate (CRF) (a ratio of deaths and positive tests) in 14 Italian regions with at least 10 cases of deaths due to COVID-19 as of 22 March 2020 (Spearman rank correlation coefficient  $\rho$ =0.657; p<0.01). Data source: www.protezionecivile.gov.it/

at the time of the article submission, from the official site of South Korea government, http://ncov.mohw.go.kr/en).

We then compiled data on the number of performed tests, positive tests, deaths, testing success and CRF in 21 countries with more than 10 deaths due to COVID-19 reported by the end of March to the beginning of April 2020 (Table 1). The relationship between the COVID-19 positive testing and case fatality rates across 21 countries is strong (Spearman rank correlation coefficient  $\rho = 0.739$ ;  $p \ll 0.01$ ). The difference between two countries Italy and South Korea in terms of a testing success, defined as a ratio of positive tests and total tested and CFR is quite apparent (Fig. 2). These findings conform to data from a study conducted in Wuhan just before the lockdown of the Hubei area in China. That study shows 55% of undocumented cases of COVID-19 were responsible for 79% of documented cases [8].






Fig. 2 The relationship between COVID-19 testing success (a ratio of positive tests and total tested) and case fatality rate (CRF) (a ratio of deaths and positive tests) in 21 countries with more than 10 deaths as of 3 March 2020 (Spearman rank correlation coefficient  $\rho$ =0.739; p<<0.01). Data sources: for total tests performed—https://ourworldindata.org/ and for positive tests and deaths—www.who.int/

# **Concluding remarks**

We want to stress that testing strategy appears to enormously affect the virus spread. A lack of definitive procedures and protocols, including guidance on clean and dirty routes for patient hospitalization, further increased virus transmission and its consequences. The high risk of exposure combined with the prolonged work shift hours, yet a low number of tests administered to doctors and healthcare workers, contributed to a high toll of severe disease and deaths among doctors and healthcare professionals.



244 P. Romagnani et al.

From our first-hand experience, observations, and complementary information on COVID-19, it has become very clear that the public must demand that decision makers take into account the knowledge provided by experts - scientists and practitioners – and follow their suggestions. The most important lessons from the Italian experience with COVID-19 are that the health systems, public media, and decision makers need to promote measures to:

- ensure early isolation of symptomatic patients and rapid identification of their contacts;
- maximize testing rapidly, especially among people with multiple daily contacts with
  infected populations, such as personnel dealing with patients (doctors and nurses,
  hospital support staff, pharmacists, funeral workers) as well as personnel with wide
  exposure to the public and workers in essential services (food supplies, newsstands,
  postal offices, public transportation and taxi drivers, public safety officers, employees of
  essential production chains);
- rapidly increase diagnostic capacity by mobilizing trained personnel capable of performing rRT-PCR on respiratory samples;
- equip the population with protective masks.

### References

- 1. Berger K. The man who saw the pandemic coming. Nautilus Retrieved, March 10, 2020
- 2. Coronavirus disease 2019 (COVID-19) symptoms. CDC USA, January 30, 2020
- 3. Chen N, Zhan M, Dang X, et al. Lancet. 2020;395:507-13.
- Hui DS, Hazar E, Madam DA, et al. 2019-nCoV epidemic threat of novel coronavirus to global health—the latest 2019 novel coronavirus outbreak in Wuhan. China J Infect Dis. 2020;91:264

  –6.
- 5. Coronavirus Disease 2019 (COVID-19) transmission. CDC, March 17, 2020
- 6. CDC tests for 2019-nCoV. CDC, February 12, 2020
- Laboratory tests for 2019 novel coronavirus (2019-nCoV in suspected human cases. WHO, March 13, 2020)
- 8. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020. https://doi.org/10.1126/science.abb3221.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### **Affiliations**

Paola Romagnani<sup>1</sup> · Guido Gnone<sup>2</sup> · Francesco Guzzi<sup>1</sup> · Simone Negrini<sup>3</sup> · Andrea Guastalla<sup>3</sup> · Francesco Annunziato<sup>1</sup> · Sergio Romagnani<sup>1</sup> · Raffaele De Palma<sup>3</sup>

- Department of Clinical and Experimental Biomedical Sciences, University of Florence, Florence, Italy
- <sup>2</sup> Genoa Aquarium Foundation, Genoa, Italy
- Department of Internal Medicine, University of Genoa and IRCCS IST-Ospedale San Martino, Genoa, Italy

